



COMPANY OVERVIEW

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company's head office is in Edmonton, Alberta, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

RECENT NEWS

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023

Jul 20 2023, 6:00 AM EDT

STOCK OVERVIEW

Symbol	AUPH
Exchange	Nasdaq
Market Cap	
Last Price	\$
52-Week Range	\$ - \$

INVESTOR RELATIONS

Aurinia@westwiche.com

MANAGEMENT TEAM

Peter Greenleaf, MBA

Director, President and CEO

Max Donley, MBA

Executive Vice President, Operations and Strategy

Sue Evans, MBA, RAC

Senior Vice President, Global Regulatory Affairs

Scott Habig

Chief Commercial Officer

Volker Knappertz, M.D.

Executive Vice President, Research and Development

Michael Martin

Chief Business Officer

Joe Miller

Chief Financial Officer

Stephen Robertson

Executive Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer

AURINIA PHARMACEUTICALS INC.

#140, 14315 – 118 Avenue
Edmonton, AB T5L 4S6
Canada

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.